BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35999150)

  • 21. Immunoconjugates for Cancer Targeting: A Review of Antibody-Drug Conjugates and Antibody-Functionalized Nanoparticles.
    Petrilli R; Pinheiro DP; de Cássia Evangelista de Oliveira F; Galvão GF; Marques LGA; Lopez RFV; Pessoa C; Eloy JO
    Curr Med Chem; 2021; 28(13):2485-2520. PubMed ID: 32484100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.
    Ceci C; Lacal PM; Graziani G
    Pharmacol Ther; 2022 Aug; 236():108106. PubMed ID: 34990642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
    Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
    Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
    Nelson BE; Meric-Bernstam F
    Annu Rev Med; 2024 Jan; 75():31-48. PubMed ID: 37758237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. G protein-coupled receptor-targeting antibody-drug conjugates: Current status and future directions.
    High P; Carmon KS
    Cancer Lett; 2023 Jun; 564():216191. PubMed ID: 37100113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody drug conjugates.
    Bakhtiar R
    Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Design of next generation antibody drug conjugates].
    Zhu GD; Fu YX
    Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
    Nagayama A; Ellisen LW; Chabner B; Bardia A
    Target Oncol; 2017 Dec; 12(6):719-739. PubMed ID: 29116596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [An overview of antibody-based cancer therapy].
    Miao QF; Shao RG; Zhen YS
    Yao Xue Xue Bao; 2012 Oct; 47(10):1261-8. PubMed ID: 23289136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-drug conjugates in hematologic malignancies.
    Leslie LA; Younes A
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developments in the use of antibody-drug conjugates.
    Burris HA
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
    Pramanik D
    Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.
    Passaro A; Jänne PA; Peters S
    J Clin Oncol; 2023 Jul; 41(21):3747-3761. PubMed ID: 37224424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel linkers and connections for antibody-drug conjugates to treat cancer and infectious disease.
    Pillow TH
    Pharm Pat Anal; 2017 Jan; 6(1):25-33. PubMed ID: 28155578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE; Cotreau M; Han TH; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.
    Singh D; Dheer D; Samykutty A; Shankar R
    J Control Release; 2021 Dec; 340():1-34. PubMed ID: 34673122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed/Refractory Lymphomas.
    Hashmi H; Darwin A; Nishihori T
    Hematol Oncol Stem Cell Ther; 2023 Jan; 16(1):21-34. PubMed ID: 36634275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy.
    Fatima SW; Khare SK
    J Control Release; 2022 Jan; 341():555-565. PubMed ID: 34906604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies and challenges for the next generation of antibody-drug conjugates.
    Beck A; Goetsch L; Dumontet C; Corvaïa N
    Nat Rev Drug Discov; 2017 May; 16(5):315-337. PubMed ID: 28303026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.